Acrivon Therapeutics (NASDAQ:ACRV) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Acrivon Therapeutics (NASDAQ:ACRV) released its earnings results on Tuesday. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.08, Yahoo Finance reports.

Acrivon Therapeutics Stock Up 1.9 %

Shares of ACRV traded up $0.13 on Thursday, reaching $7.15. The stock had a trading volume of 1,970 shares, compared to its average volume of 363,870. The firm has a market capitalization of $220.77 million, a PE ratio of -2.44 and a beta of 0.79. The firm has a 50-day moving average of $7.21 and a 200 day moving average of $6.86. Acrivon Therapeutics has a twelve month low of $3.19 and a twelve month high of $12.52.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ACRV shares. LADENBURG THALM/SH SH downgraded Acrivon Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, April 29th. JMP Securities upped their price objective on Acrivon Therapeutics from $14.00 to $17.00 and gave the company a “market outperform” rating in a research note on Thursday, April 25th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a research note on Tuesday. Piper Sandler upped their price objective on Acrivon Therapeutics from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Acrivon Therapeutics in a research note on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.57.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.